Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 26 2015


Gallus Enters ADC Mfg. Agreement with Progenics

Published August 21, 2014
Related Searches: Manufacturing
Gallus BioPharmaceuticals, LLC has been selected by Progenics Pharmaceuticals, Inc. to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in its PSMA ADC product candidate. Gallus will produce the antibody at its commercial manufacturing facility in St. Louis, MO.
PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug to prostate cancer cells by targeting PSMA, a protein that is a biomarker of prostate cancer. The PSMA antibody is designed enter the cancer cell and release active anti-cancer drug.
“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody," said Mark R. Bamforth, president and chief executive officer of Gallus. "We look forward to working with Progenics as they advance this treatment for patients with prostate cancer."
"Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, Ph.D., senior vice president of manufacturing at Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy."

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On